EE316 The Cost-Saving of the Introduction of Dapagliflozin in Algeria After Primary Failure of Oral Anti-Diabetics in Patients With Types 2 Diabetes (T2DM)
Dec 1, 2023, 00:00
10.1016/j.jval.2023.09.582
https://www.valueinhealthjournal.com/article/S1098-3015(23)03712-9/fulltext
Title :
EE316 The Cost-Saving of the Introduction of Dapagliflozin in Algeria After Primary Failure of Oral Anti-Diabetics in Patients With Types 2 Diabetes (T2DM)
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(23)03712-9&doi=10.1016/j.jval.2023.09.582
First page :
Section Title :
Open access? :
No
Section Order :
10075